Neurology® Podcast

The February 2026 recall features four previously posted episodes on multiple sclerosis. The episode begins with a conversation with Dr. Wallace J. Brownle discussing whether dissemination in time is essential to diagnois relapsing MS. The discussion continues with Dr. Daniel Ontaneda regarding the 2024 revisions of the McDonald criteria for diagnosing multiple sclerosis. The episode then transitions into a conversation with Dr. Jiwon Oh about BTK inhibitors and recent data on tolebrutinib in multiple sclerosis. The episode concludes with Dr. Sandra Vukusic addressing the differences in disease-modifying therapies for female versus male patients with multiple sclerosis. 
Podcast link:
Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing MS
2024 McDonald Criteria 
BTK Inhibitors in Multiple Sclerosis Treatment
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis
Podcast article:
Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis 
Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria 
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis 
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis 
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis
Disclosures can be found at Neurology.org.

Dr. Tesha Monteith talks with Dr. Michael Eller about the implications of CGRP therapies in migraine treatment, particularly for patients with vascular risk factors or a history of stroke. 
Read the related article in Neurology®.
Disclosures can be found at Neurology.org.

Dr. Stacey Clardy talks with Dr. John Ney about the prevalence, disability burden, and societal impact of neurologic disorders in the U.S. 
Read the related article in JAMA. 
Disclosures can be found at Neurology.org.

In the second episode of this two-part series, Dr. Justin Abbatemarco talks with Drs. Valérie Biousse and Nancy J. Newman about the management of non-arteritic ischemic optic neuropathy and its emerging relationship with GLP‑1 medications. 
Disclosures can be found at Neurology.org.

In part one of this two-part series, Dr. Justin Abbatemarco talks with Drs. Valérie Biousse and Nancy J. Newman about the clinical features and diagnostic tools utilized for non-arteritic ischemic optic neuropathy (NAION). 
Disclosures can be found at Neurology.org.